In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Real-world dosing of renin-angiotensin-aldosterone system inhibitors in heart failure patients, and associations between hyperkalaemia and down-titration or discontinuation

Session Poster Session 6

Speaker Cecilia Linde

Congress : ESC Congress 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P5671

Authors : C Linde (Stockholm,SE), P Mcewan (Cardiff,GB), A Bakhai (London,GB), H Furuland (Uppsala,SE), M Evans (Cardiff,GB), D Ayoubkhani (Cardiff,GB), S Grandy (Gaithersburg,US), E Palaka (Cambridge,GB), L Qin (Gaithersburg,US)

Authors:
C. Linde1 , P. McEwan2 , A. Bakhai3 , H. Furuland4 , M. Evans5 , D. Ayoubkhani2 , S. Grandy6 , E. Palaka7 , L. Qin6 , 1Karolinska University Hospital, Heart and Vascular Theme - Stockholm - Sweden , 2Health Economics and Outcomes Research Ltd - Cardiff - United Kingdom , 3Royal Free Hospital, Department of Cardiology - London - United Kingdom , 4Uppsala University Hospital, Department of Nephrology - Uppsala - Sweden , 5University Hospital Llandough, Diabetes Resource Centre - Cardiff - United Kingdom , 6AstraZeneca, Global Health Economics - Gaithersburg - United States of America , 7AstraZeneca, Global Health Economics - Cambridge - United Kingdom ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1194

Background: Down-titration or discontinuation of renin-angiotensin-aldosterone system inhibitors (RAASi) is common practice to reduce iatrogenic hyperkalaemia (HK) in heart failure (HF) patients. However, RAASi dose modification may reduce its cardio-renal protection.

Purpose: To study RAASi dosing in HF patients, including the association between HK and down-titration/discontinuation of RAASi therapies.

Methods: Data from the UK Clinical Practice Research Datalink identified patients with a new diagnosis of HF from Jan 2006 to Dec 2015 without chronic kidney disease (stage 3+). Serum potassium (K+) was time-updated during follow-up. HK was categorised using the thresholds K+ ≥5.0, ≥5.5 and ≥6.0 mmol/L; normokalaemia was defined as K+ 3.5 to <5.0 mmol/L. RAASi therapies included ACEi, ARBs and MRAs. Outcomes included: prescribed RAASi daily dose (DD) as a percentage of ESC-recommended DD; down-titration, defined as a decrease in prescribed DD between successive prescriptions; and discontinuation, defined as a minimum 90-day gap in the supply. DDs were assessed within 7 days from each K+ measurement. Generalized Estimating Equations were used to estimate adjusted odds ratios (ORs) relating RAASi down-titration/discontinuation to HK whilst controlling for confounders, including patient demographics, clinical measurements (e.g. eGFR), and concomitant medications.

Results: Of 21,334 eligible HF patients, 13,113 (61%) received RAASi during follow-up (mean follow-up 5.1 years). At baseline, the mean age was 73 years, 60% male, and 16%, 12% and 7% had diabetes, myocardial infarction or stroke, respectively. During follow-up, 5,580 (43%), 2,070 (16%) and 601 (5%) patients experienced at least one HK event at K+ ≥5.0, ≥5.5, and ≥6.0 mmol/L, respectively. Prescriptions recorded for ACEi, ARBs and MRAs were 250,842 (54%), 92,569 (20%) and 118,079 (26%), respectively. In 65% of patients, prescribed RAASi DD was less than 100% of ESC-recommended dose, with 26% prescribed less than 50% of recommended. RAASi dose was reduced in 4%, 6% and 9% of prescriptions issued within 7 days of K+ measurements of ≥5.0, ≥5.5, and ≥6.0 mmol/L, respectively, compared to 3% of prescriptions during normokalaemia. The corresponding percentages of RAASi discontinuation were 4%, 6% and 10% after K+ measurements of ≥5.0, ≥5.5, and ≥6.0 mmol/L, respectively, compared to 3% during normokalaemia. Figure 1 illustrates ORs for RAASi down-titration and discontinuation, comparing patients with and without HK at different K+ thresholds, after controlling for covariates.

Conclusion: In this real-world HF cohort analysis, most patients were below recommended RAASi daily dose. The likelihood of down-titration post HK was significantly associated with, and proportional to the magnitude of elevated K+. Therapies to manage HK would allow patients to be maintained on recommended RAASi dose for cardio-renal benefits; further prospective studies are warranted to evaluate this.

Figure 1


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are